20.08

2.34% 0.46

Jade Biosciences Inc (JBIO)

Overview News Price History Discussions Forecast

Jade Biosciences Inc stock is traded at $20.08, with a volume of 684.57K. It is up +2.34% in the last 24 hours and down -8.31% over the past month. Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.

Previous Close:

$19.62

Open:

$19.77

24h Volume:

684.57K

Relative Volume:

0.67

Market Cap:

$1.22B

Revenue:

Net Income/Loss:

$-129.61M

P/E Ratio:

-6.7222

EPS:

-2.9871

Net Cash Flow:

$-116.59M

1W Performance:

-3.74%

1M Performance:

-8.31%

6M Performance:

+23.15%

1Y Performance:

+141.06%

1-Day Range:

$19.02

$20.10

1-Week Range:

$19.02

$21.50

52-Week Range:

$6.67

$28.00

Jade Biosciences Inc Stock (JBIO) Company Profile

Name

Jade Biosciences Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

(781) 312-3013

Address

221 CRESCENT ST., WALTHAM

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

JBIO's Discussions on Twitter

Compare JBIO vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JBIO Jade Biosciences Inc	20.08	1.22B	0	-129.61M	-116.59M	-2.9871
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	H.C. Wainwright	Buy
Oct-09-25	Initiated	BTIG Research	Buy
Jul-14-25	Initiated	Jefferies	Buy
Jun-16-25	Upgrade	Guggenheim	Neutral → Buy
May-07-25	Initiated	Wedbush	Outperform
May-05-25	Initiated	Stifel	Buy
May-02-25	Initiated	TD Cowen	Buy
Jun-18-24	Downgrade	Evercore ISI	Outperform → In-line
Jun-18-24	Downgrade	TD Cowen	Buy → Hold
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Jun-17-24	Downgrade	Guggenheim	Buy → Neutral
Jun-17-24	Downgrade	Wedbush	Outperform → Neutral
Mar-25-24	Resumed	Jefferies	Buy
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Mar-01-23	Initiated	Guggenheim	Buy
Dec-06-22	Upgrade	BTIG Research	Neutral → Buy
Sep-19-22	Resumed	Wedbush	Outperform
Aug-16-22	Downgrade	BTIG Research	Buy → Neutral
Feb-11-22	Initiated	BTIG Research	Buy
Jul-26-21	Initiated	Cowen	Outperform
Jul-26-21	Initiated	Evercore ISI	Outperform
Jul-26-21	Initiated	Jefferies	Buy
Jul-26-21	Initiated	Wedbush	Outperform

View All

Jade Biosciences Inc Stock (JBIO) Latest News

03:22 AM

Affinity Asset Advisors LLC Decreases Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat

03:22 AM

Jul 24, 2026

Jade Biosciences, Inc. Revenue Breakdown – NASDAQ:JBIO - TradingView

Jul 24, 2026

Paradigm Biocapital Advisors LP Acquires Significant Stake in Ja - GuruFocus

Jul 24, 2026

Jul 23, 2026

Paradigm Biocapital Advisors LP Acquires Significant Stake in Jade Biosciences Inc - GuruFocus

Jul 23, 2026

Jul 18, 2026

Jade Biosciences Company Profile & Introduction - Moomoo

Jul 18, 2026

Jul 17, 2026

Paradigm funds disclose significant Jade Biosciences (JBIO) ownership in Schedule 13G - Stock Titan

Jul 17, 2026

Jul 13, 2026